Anavex Life Sciences (AVXL) Other Gross PP&E Adjustments (2015 - 2025)
Anavex Life Sciences recorded quarterly Other Gross PP&E Adjustments of -$23.2 million in Q3 2025, down 9.93% quarter-over-quarter from -$21.1 million in Q3 2024, and down 9.93% year-over-year from -$25.7 million in Q3 2024.
Anavex Life Sciences' Other Gross PP&E Adjustments history runs 11 years deep, the most recent figure standing at -$23.2 million for Q3 2025.
- In Q3 2025, Other Gross PP&E Adjustments fell 9.93% year-over-year to -$23.2 million; the TTM figure through Dec 2025 stood at -$23.2 million (down 9.93% YoY), while the FY2025 annual figure was -$23.2 million, down 9.93% from the prior year.
- Other Gross PP&E Adjustments came in at -$23.2 million for Q3 2025 at Anavex Life Sciences, down from -$21.1 million in the prior quarter.
- In the past five years, Other Gross PP&E Adjustments ranged from a high of -$10.5 million in Q3 2021 to a low of -$23.2 million in Q3 2025.
- A 5-year average of -$17.3 million and a median of -$18.6 million in 2023 frame the typical range for Other Gross PP&E Adjustments.
- Across the five-year window, Other Gross PP&E Adjustments slumped 39.03% in 2023 and slipped 9.93% in 2025, its largest moves.
- Anavex Life Sciences' Other Gross PP&E Adjustments stood at -$10.5 million in 2021, then decreased by 27.93% to -$13.4 million in 2022, then slumped by 39.03% to -$18.6 million in 2023, then slipped by 13.44% to -$21.1 million in 2024, then fell by 9.93% to -$23.2 million in 2025.
- According to Business Quant data, Other Gross PP&E Adjustments over the past three periods registered -$23.2 million, -$21.1 million, and -$18.6 million for Q3 2025, Q3 2024, and Q3 2023 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Gross PP&E Adjustments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -83,048.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -60,691.22 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -285.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -892,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -1.69 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -189.30 Mn |
| 10 | Anavex Life Sciences | 266.20 Mn | 134.45 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -23.19 Mn |
| Sep 30, 2025 | -23.19 Mn |
| Sep 30, 2024 | -21.09 Mn |
| Sep 30, 2024 | -21.09 Mn |
| Sep 30, 2023 | -18.59 Mn |
| Sep 30, 2023 | -18.59 Mn |
| Sep 30, 2022 | -13.37 Mn |
| Sep 30, 2022 | -13.37 Mn |
| Sep 30, 2021 | -10.45 Mn |
| Sep 30, 2021 | -10.45 Mn |
| Sep 30, 2020 | -8.28 Mn |
| Sep 30, 2020 | -8.28 Mn |
| Sep 30, 2019 | -6.57 Mn |
| Sep 30, 2019 | -6.57 Mn |
| Sep 30, 2018 | -4.68 Mn |
| Sep 30, 2018 | -4.68 Mn |
| Sep 30, 2017 | -3.39 Mn |
| Sep 30, 2017 | -3.39 Mn |
| Sep 30, 2016 | -2.00 Mn |
| Sep 30, 2016 | -2.00 Mn |
| Sep 30, 2015 | -581,000.00 |
| Sep 30, 2015 | -581,000.00 |